ABSTRACT BACKGROUND LncRNA FGF14-AS2 is a critical suppressor in breast cancer (BCa) metastasis. However, whether FGF14-AS2 plays a role in the bone metastasis of BCa remains unknown.

METHODS TRAP assay and intratibial injection were carried out to evaluate the role of FGF14-AS2 in BCa bone metastasis in vitro and in vivo. Polyribosome profiling was done to examine the

translation level. RNA pulldown combined with LC/MS was performed to identify the lncRNA-binding partner, RIP, dual-luciferase assay, and Co-IP assays as well to testify these physical

interactions. The prognostic value of FGF14-AS2 expression level in BCa patients was analysed using Kaplan–Meier Plotter. RESULTS We found that FGF14-AS2 suppresses osteoclast

m6A-dependent manner. Clinically, patients with high YTHDF2 and low FGF14-AS2 expression levels showed worse distant metastasis-free survival (DMFS). CONCLUSIONS FGF14-AS2 plays a crucial

role in osteolytic metastasis, and may serve as a promising prognostic biomarker and therapeutic target for BCa bone metastasis. Access through your institution Buy or subscribe This is a

preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 24 print issues and online access $259.00 per

year only $10.79 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support SIMILAR CONTENT BEING VIEWED BY OTHERS ABERRANT

NSUN2-MEDIATED M5C MODIFICATION OF EXOSOMAL LNCRNA MALAT1 INDUCED RANKL-MEDIATED BONE DESTRUCTION IN MULTIPLE MYELOMA Article Open access 02 October 2024 TUMOUR-DERIVED EXOSOMAL

LNCRNA-SOX2OT PROMOTES BONE METASTASIS OF NON-SMALL CELL LUNG CANCER BY TARGETING THE MIRNA-194-5P/RAC1 SIGNALLING AXIS IN OSTEOCLASTS Article Open access 02 July 2021 LSD1 MODULATES THE

BONE METASTASIS OF BREAST CANCER CELLS THROUGH HNRNPA2B1-MEDIATED SORTING OF EXOSOMAL MIRNAS Article Open access 06 March 2024 DATA AVAILABILITY All the data that support the findings of

this study are available from the corresponding author upon reasonable request. REFERENCES * Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer

statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca Cancer J Clin. 2021;71:209–49. Article  PubMed  Google Scholar  * Solanki M,

Visscher D. Pathology of breast cancer in the last half century. Hum Pathol. 2020;95:137–48. Article  PubMed  Google Scholar  * Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E,

Fallon M, et al. Bone metastases. Nat Rev Dis Primers. 2020; https://doi.org/10.1038/s41572-020-00216-3. * Liang Y, Zhang H, Song X, Yang Q. Metastatic heterogeneity of breast cancer:

molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27. Article  CAS  PubMed  Google Scholar  * Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to

the bone: mechanisms of bone loss. Breast Cancer. Res. 2010; https://doi.org/10.1186/bcr2781. * Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: an

overview. Oncol Rev. 2017; https://doi.org/10.4081/oncol.2017.321. * Pathi SP, Lin DD, Dorvee JR, Estroff LA, Fischbach C. Hydroxyapatite nanoparticle-containing scaffolds for the study of

breast cancer bone metastasis. Biomaterials. 2011;32:5112–22. Article  CAS  PubMed  PubMed Central  Google Scholar  * Futakuchi M, Fukamachi K, Suzui M. Heterogeneity of tumor cells in the

bone microenvironment: mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. Adv Drug Deliv Rev. 2016;99:206–11. Article  CAS  PubMed  Google Scholar  *

Schramek D, Sigl V, Penninger JM. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis. Trends Endocrinol Metab. 2011;22:188–94. Article  CAS  PubMed  Google

Scholar  * Azim H, Azim HA Jr. Targeting RANKL in breast cancer: bone metastasis and beyond. Expert Rev Anticancer Ther. 2013;13:195–201. Article  CAS  PubMed  Google Scholar  * Wu X, Li F,

Dang L, Liang C, Lu A, Zhang G. RANKL/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies. Front Cell Dev Biol. 2020;

https://doi.org/10.3389/fcell.2020.00076. * Galea GL, Paradise CR, Meakin LB, Camilleri ET, Taipaleenmaki H, Stein GS, et al. Mechanical strain-mediated reduction in RANKL expression is

associated with RUNX2 and BRD2. Gene. 2020; https://doi.org/10.1016/j.gene.2020.100027. * Barnes GL, Hebert KE, Kamal M, Javed A, Einhorn TA, Lian JB, et al. Fidelity of Runx2 activity in

breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 2004;64:4506–13. Article  CAS  PubMed  Google Scholar  * Javed A, Barnes GL,

Pratap J, Antkowiak T, Gerstenfeld LC, van Wijnen AJ, et al. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo.

Proc Natl Acad Sci USA. 2005;102:1454–9. Article  CAS  PubMed  PubMed Central  Google Scholar  * Choi SW, Kim HW, Nam JW. The small peptide world in long noncoding RNAs. Brief Bioinform.

2019;20:1853–64. Article  CAS  PubMed  PubMed Central  Google Scholar  * Xu Y, Ren W, Li Q, Duan C, Lin X, Bi Z, et al. LncRNA Uc003xsl.1-mediated activation of the NFκB/IL8 axis promotes

progression of triple-negative breast cancer. Cancer Res. 2022;82:556–70. Article  CAS  PubMed  Google Scholar  * Chu Z, Huo N, Zhu X, Liu H, Cong R, Ma L, et al. FOXO3A-induced LINC00926

suppresses breast tumor growth and metastasis through inhibition of PGK1-mediated Warburg effect. Mol Ther. 2021;29:2737–53. Article  CAS  PubMed  PubMed Central  Google Scholar  * Rajagopal

T, Talluri S, Akshaya RL, Dunna NR. HOTAIR LncRNA: a novel oncogenic propellant in human cancer. Clin Chim Acta. 2020;503:1–18. Article  CAS  PubMed  Google Scholar  * Ghafouri-Fard S,

Dashti S, Taheri M. PCAT1: an oncogenic lncRNA in diverse cancers and a putative therapeutic target. Exp Mol Pathol. 2020; https://doi.org/10.1016/j.yexmp.2020.104429. * Jin Y, Zhang M, Duan

R, Yang J, Yang Y, Wang J, et al. Long noncoding RNA FGF14-AS2 inhibits breast cancer metastasis by regulating the miR-370-3p/FGF14 axis. Cell Death Discov. 2020;

https://doi.org/10.1038/s41420-020-00334-7. * Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem

Biol. 2014;10:93–5. Article  CAS  PubMed  Google Scholar  * Wang Y, Li Y, Toth JI, Petroski MD, Zhang Z, Zhao JC. N6-methyladenosine modification destabilizes developmental regulators in

embryonic stem cells. Nat Chem Biol. 2014;16:191–8. CAS  Google Scholar  * Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, et al. ALKBH5 is a mammalian RNA demethylase that impacts

RNA metabolism and mouse fertility. Mol Cell. 2013;49:18–29. Article  CAS  PubMed  Google Scholar  * Li Y, Wu K, Quan W, Yu L, Chen S, Cheng C, et al. The dynamics of FTO binding and

demethylation from the m(6)A motifs. Rna Biol. 2019;16:1179–89. Article  PubMed  PubMed Central  Google Scholar  * Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, et al. YTHDF3 facilitates

translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27:315–28. Article  CAS  PubMed  PubMed Central  Google Scholar  * Deng J, Zhang J, Ye Y, Liu K, Zeng L, Huang J,

et al. N(6) -methyladenosine-mediated upregulation of WTAPP1 promotes WTAP translation and Wnt signaling to facilitate pancreatic cancer progression. Cancer Res. 2021;81:5268–83. Article 

CAS  PubMed  Google Scholar  * Li B, Zhu L, Lu C, Wang C, Wang H, Jin H, et al. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor

immunity. Nat Commun. 2021; https://doi.org/10.1038/s41467-020-20527-z. * Chen Y, Lin Y, Shu Y, He J, Gao W. Interaction between N(6)-methyladenosine (m(6)A) modification and noncoding RNAs

in cancer. Mol Cancer. 2020; https://doi.org/10.1186/s12943-020-01207-4. * Lan Q, Liu PY, Haase J, Bell JL, Hüttelmaier S, Liu T. The critical role of RNA m(6)A methylation in cancer.

Cancer Res. 2019;79:1285–92. Article  CAS  PubMed  Google Scholar  * Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, et al. METTL3-mediated m(6)A modification of HDGF mRNA promotes gastric

cancer progression and has prognostic significance. Gut. 2020;69:1193–205. Article  CAS  PubMed  Google Scholar  * Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, et al. The m6A reader YTHDF1

promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48:3816–31. Article  CAS  PubMed  PubMed Central  Google Scholar  * Yang J, Zhang M, Yang D, Ma

Y, Tang Y, Xing M, et al. m(6)A-mediated upregulation of AC008 promotes osteoarthritis progression through the miR-328-3p‒AQP1/ANKH axis. Exp Mol Med. 2021;53:1723–34. Article  CAS  PubMed 

PubMed Central  Google Scholar  * Lou WP, Baser A, Klußmann S, Martin-Villalba A. In vivo interrogation of central nervous system translatome by polyribosome fractionation. J Vis Exp. 2014;

https://doi.org/10.3791/51255. * Shore P. A role for Runx2 in normal mammary gland and breast cancer bone metastasis. J Cell Biochem. 2005;96:484–9. Article  CAS  PubMed  Google Scholar  *

Li XQ, Lu JT, Tan CC, Wang QS, Feng YM. RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization. Cancer Lett. 2016;380:78–86. Article  CAS  PubMed 

Google Scholar  * Novikova IV, Hennelly SP, Sanbonmatsu KY. Structural architecture of the human long non-coding RNA, steroid receptor RNA activator. Nucleic Acids Res. 2012;40:5034–51.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Lu C, Makala L, Wu D, Cai Y. Targeting translation: eIF4E as an emerging anticancer drug target. Expert Rev Mol Med. 2016;

https://doi.org/10.1017/erm.2015.20. * Yang Y, Xun N, Wu JG. Long non-coding RNA FGF14-AS2 represses proliferation, migration, invasion, and induces apoptosis in breast cancer by sponging

miR-205-5p. Eur Rev Med Pharmacol Sci. 2019;23:6971–82. CAS  PubMed  Google Scholar  * Li F, Zhao D, Wu J, Shi Y. Structure of the YTH domain of human YTHDF2 in complex with an m(6)A

mononucleotide reveals an aromatic cage for m(6)A recognition. Cell Res. 2014;24:1490–2. Article  PubMed  PubMed Central  Google Scholar  * Zhu T, Roundtree IA, Wang P, Wang X, Wang L, Sun

C, et al. Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine. Cell Res. 2014;24:1493–6. Article  CAS  PubMed  PubMed Central  Google

Scholar  * Tiedemann K, Hussein O, Komarova SV. Role of altered metabolic microenvironment in osteolytic metastasis. Front Cell Dev Biol. 2020; https://doi.org/10.3389/fcell.2020.00435. *

Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965–81. Article  CAS  PubMed  PubMed Central  Google Scholar  * Lang C, Dai Y, Wu Z, Yang

Q, He S, Zhang X, et al. SMAD3/SP1 complex-mediated constitutive active loop between lncRNA PCAT7 and TGF-β signaling promotes prostate cancer bone metastasis. Mol Oncol. 2020;14:808–28.

Article  CAS  PubMed  PubMed Central  Google Scholar  * Zhang L, Niu H, Ma J, Yuan BY, Chen YH, Zhuang Y, et al. The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis

in hepatocellular carcinoma. Mol Cancer. 2019; https://doi.org/10.1186/s12943-019-1044-9. * Li C, Wang S, Xing Z, Lin A, Liang K, Song J, et al. A ROR1-HER3-lncRNA signalling axis modulates

the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19:106–19. Article  CAS  PubMed  PubMed Central  Google Scholar  * Grüner S, Peter D, Weber R, Wohlbold L, Chung MY,

Weichenrieder O, et al. The structures of eIF4E-eIF4G complexes reveal an extended interface to regulate translation initiation. Mol Cell. 2016;64:467–79. Article  PubMed  Google Scholar  *

Bramham CR, Jensen KB, Proud CG. Tuning specific translation in cancer metastasis and synaptic memory: control at the MNK-eIF4E axis. Trends Biochem Sci. 2016;41:847–58. Article  CAS  PubMed

  Google Scholar  * Silva AM, Whitmore M, Xu Z, Jiang Z, Li X, Williams BR. Protein kinase R (PKR) interacts with and activates mitogen-activated protein kinase kinase 6 (MKK6) in response

to double-stranded RNA stimulation. J Biol Chem. 2004;279:37670–6. Article  CAS  PubMed  Google Scholar  * Wu Y, Yang X, Chen Z, Tian L, Jiang G, Chen F, et al. m(6)A-induced lncRNA RP11

triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer. 2019; https://doi.org/10.1186/s12943-019-1014-2. * Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J,

et al. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol. 2020;

https://doi.org/10.1186/s13045-019-0839-x. Download references FUNDING This work was supported by grants from the National Natural Science Foundation of China (No. 81872389, 81570804 and

82072484); the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Key Project of Science; the Major Projects of Science and Technology Development Fund

of Nanjing Medical University (No. NMUD2019004). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Medical Genetics, Nanjing Medical University, Longmian Road 101, 211166, Nanjing,

P.R. China Ming Zhang, Yucui Jin, Que Zheng, Mengying Xing, Yuting Tang, Yunfei Ma, Lingyun Li, Bing Yao & Changyan Ma * Jiangsu Key Laboratory of Xenotransplantation, Nanjing Medical

University, Longmian Road 101, 211166, Nanjing, P.R. China Ming Zhang & Changyan Ma * Division of Breast Surgery, the First Affiliated Hospital with Nanjing Medical University, Guangzhou

Road 300, 210029, Nanjing, Jiangsu Province, P.R. China Jue Wang * Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Guangzhou Road 300, 210029, Nanjing,

Jiangsu Province, P.R. China Hao Wu Authors * Ming Zhang View author publications You can also search for this author inPubMed Google Scholar * Jue Wang View author publications You can also

search for this author inPubMed Google Scholar * Yucui Jin View author publications You can also search for this author inPubMed Google Scholar * Que Zheng View author publications You can

also search for this author inPubMed Google Scholar * Mengying Xing View author publications You can also search for this author inPubMed Google Scholar * Yuting Tang View author

publications You can also search for this author inPubMed Google Scholar * Yunfei Ma View author publications You can also search for this author inPubMed Google Scholar * Lingyun Li View

author publications You can also search for this author inPubMed Google Scholar * Bing Yao View author publications You can also search for this author inPubMed Google Scholar * Hao Wu View

author publications You can also search for this author inPubMed Google Scholar * Changyan Ma View author publications You can also search for this author inPubMed Google Scholar

CONTRIBUTIONS MZ, MX and YT performed the experiments. WJ provided the clinical samples. MZ performed the statistical analysis. YM and YJ performed the bioinformatic analyses. HW and QZ

reviewed the data. LL, BY, YJ and CM designed the research and drafted the manuscript. CORRESPONDING AUTHOR Correspondence to Changyan Ma. ETHICS DECLARATIONS COMPETING INTERESTS The authors

declare no competing interests. ETHICS APPROVAL AND CONSENT TO PARTICIPATE All procedures performed in studies involving human participants were in accordance with the ethical standards of

the Ethics Committee of Nanjing Medical University (Approval number: 2018-487) and with the Declaration of Helsinki and its later amendments or comparable ethical standards, and all patients

provided written informed consent. CONSENT TO PUBLISH Not applicable. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in

published maps and institutional affiliations. SUPPLEMENTARY INFORMATION SUPPLEMENTAL METHODS SUPPLEMENTAL FIGURE LEGENDS SUPPLEMENTAL FIG. 1 SUPPLEMENTAL FIG. 2 SUPPLEMENTAL FIG. 3

SUPPLEMENTAL FIG. 4 SUPPLEMENTAL FIG. 5 SUPPLEMENTAL FIG. 6 TABLE S1 TABLE S2 TABLE S3 TABLE S4 TABLE S5 TABLE S6 TABLE S7 RIGHTS AND PERMISSIONS Springer Nature or its licensor holds

exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely

governed by the terms of such publishing agreement and applicable law. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Zhang, M., Wang, J., Jin, Y. _et al._ YTHDF2-mediated

FGF14-AS2 decay promotes osteolytic metastasis of breast cancer by enhancing RUNX2 mRNA translation. _Br J Cancer_ 127, 2141–2153 (2022). https://doi.org/10.1038/s41416-022-02006-y Download

citation * Received: 15 May 2022 * Revised: 26 September 2022 * Accepted: 27 September 2022 * Published: 10 October 2022 * Issue Date: 07 December 2022 * DOI:

https://doi.org/10.1038/s41416-022-02006-y SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative